tiprankstipranks
Sarissa Capital announces proxy contest win against Amarin
The Fly

Sarissa Capital announces proxy contest win against Amarin

Sarissa Capital Management issued the following statement regarding Amarin: "Amarin shareholders have sent a loud and clear message repudiating the incumbent Amarin board. Sarissa thanks fellow shareholders for their support in a resounding victory against the Amarin board. Our estimate is that up to nearly 80% of shareholder votes were in support of Sarissa. As Amarin’s largest shareholder, we are grateful for the opportunity to remake Amarin for the benefit of all shareholders. Vascepa, the foundation on which Amarin is built, is a tremendous drug that is compelling for patients and payors – a unique proposition for a drug. While there is a lot of work to be done, we remain confident in our ability to leverage Vascepa’s rare and highly beneficial profile to unlock tremendous value for all shareholders."

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on AMRN:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles